Table 4.
NP-based combined PTT/PDT.a
| The NPs | PT agents | PSs | Laser (nm) | In vitro anti-cancer effect | Particles injection dosage of in vivo anti-cancer study | In vivo anti-cancer effect | Reference |
|---|---|---|---|---|---|---|---|
| Ce6-loaded MoS2-PEG | MoS2 | Ce6 | 808/660 | 4T1 cell viability: less than 20% | Ce6: 2 mg/kg, MoS2-PEG: 6.85 mg/kg | 4T1 tumor volume smaller than 140 mm3 | [239] |
| AuNR/ICG/PEG-PCL | ICG and Au nanorods | ICG | 785 | About 15% of PC3 tumor cells underwent apoptosis under 3 min' light excitation | 7.5 mg/kg (equivalent ICG content) | 60% PC3 tumor-bearing mice were cured. | [240] |
| NaGdY4-UCNP@BSA-RB&IR825 | IR825 | RB | 808/980 | 4T1 cell viability: less than 10% | 20 μL (10 mg/mL) | 4T1 tumor volume less than 50 mm3 | [241] |
| Gd2O3@PPy/AlPc-HA | PPy | AlPc | 808/670 | 4T1 cell viability: 20% | 20 μL (2 mg/mL) | Combined PTT/PDT demonstrated the best therapeutic efficiency for 4T1 tumor, better than any single therapy | [242] |
| MnO2@Ce6@PDA-FA | PDA | Ce6 | 808/660 | MCF-7 cell viability:10% | MnO2: 10 mg/kg, Ce6: 5 mg/kg | The most pronounced MCF-7 tumor growth inhibition in mice was observed upon combined therapy | [235] |
| PFOB @IR780& mTHPC@ NAcHis-TPGS modified liposome | IR780 | mTHPC | 808/660 | TRAMP-C1 cell viability: less than 10% | mTHPC: 2.43 mg/kg, IR 780: 2.5 mg/kg | TRAMP-C1 tumors remained essentially the same size with the combination therapy, the full inhibition of tumor growth | [243] |
| MoO3-x-Ag-PEG-MnO2 | Ag nanocubes | MoO3-x | 808 | HeLa cell viability less than 20% | 20 μL (5 mg/mg equivalent [Mo] concentration) | HeLa tumor was completely ablated | [244] |
| 17AAG@ P(2PMI-AQ) | 2PMI-AQ | 2PMI-AQ | 660 | 4T1 cell viability: less than 20% | 10 mg/kg | The most efficient suppression of 4T1 tumor growth | [245] |
| MSNR@Au-TPPS4(Gd) | Au | TPPS4(Gd) | 808/660 | 4T1 cell viability: less than 30% | No dose information were provided. | The best treatment effect on 4T1 tumors under combination therapy compared with any single therapy | [246] |
| [PHC]PP@HA NPs | PDA | Ce6 | 808/670 | PC-3 cell viability: less than 10% both in normoxia and hypoxia | 4 mg/kg (equivalent Ce6 content) | The best PC-3 tumor inhibition, close to 100% of tumor inhibition rate and the tumor growth curves remained unchanged within 20 days | [247] |
| MC/MnO2/Ce6/CCM | MC | Ce6 | 808/660 | 4T1 cell viability: 25% | Four times injections: each time: 5 mg/kg (equivalent Ce6 content) | The best 4T1 tumor suppression rate: 93% and had the highest apoptosis or necrosis | [59] |
| MC/MnO2/Ce6/PEG/iRGD | MC | Ce6 | 808/660 | 4T1 cell IC50: 0.843 μg/mL | 5 mg/kg (equivalent Ce6 content) | The best therapeutic effect on the 4T1 tumor and some 4T1 tumors were completely ablated | [58] |
a
The undefined abbreviations in the table: folic acid (FA), metatetra(hydroxyphenyl)chlorin (mTHPC), aluminum phthalocyanine (AlPc), allylamino-17-demethoxygeldanamycin (17AAG), two perylene monoimide moieties-diamino anthraquinone (2PMI-AQ), 5,10,15,20-Tetrakis (4-sulfonatophenyl)-porphyrin (TPPS4), PDA-hemoglobin-Ce6 (PHC), Mesoporous carbon (MC).